Truncated thioredoxin (Trx-80) promotes pro-inflammatory macrophages of the M1 phenotype and enhances atherosclerosis

Journal of Cellular Physiology

Volumn 228, Issue 7, 2013, Pages 1577-1583

  Mahmood, Dler Faieeq Darweesh ^a   Abderrazak, Amna ^a   Couchie, Dominique ^a   Lunov, Oleg ^b   Diderot, Vimala ^a   Syrovets, Tatiana ^b   Slimane, Mohamed Naceur ^c   Gosselet, Fabien ^d   Simmet, Thomas ^b   Rouis, Mustapha ^a   El Hadri, Khadija ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY OF MONASTIR   (Tunisia)

^d UNIVERSITÉ D'ARTOIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD206 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; THIOREDOXIN; THIOREDOXIN 80; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYPERLIPOPROTEINEMIA; IN VITRO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PHENOTYPE; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; APOLIPOPROTEIN E2; ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; HUMANS; INFLAMMATION; LECTINS, C-TYPE; MACROPHAGES; MANNOSE-BINDING LECTINS; MICE; MICE, INBRED C57BL; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; PHENOTYPE; RECEPTORS, CELL SURFACE; THIOREDOXINS;

MUS;

EID: 84875549616     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24319     Document Type: Article

References (41)

1. Andoh T, Chock PB, Chiueh CC. 2002. The roles of thioredoxin in protection against oxidative stress-induced apoptosis in SH-SY5Y cells. J Biol Chem 277: 9655-9660.
2. Bertini R, Howard OM, Dong HF, Oppenheim JJ, Bizzarri C, Sergi R, Caselli G, Pagliei S, Romines B, Wilshire JA, Mengozzi M, Nakamura H, Yodoi J, Pekkari K, Gurunath R, Holmgren A, Herzenberg LA, Herzenberg LA, Ghezzi P. 1999. Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells. J Exp Med 189: 1783-1789.
3. Billiet L, Furman C, Larigauderie G, Copin C, Brand K, Fruchart JC, Rouis M. 2005. Extracellular human thioredoxin-1 inhibits lipopolysaccharide-induced interleukin-1beta expression in human monocyte-derived macrophages. J Biol Chem 280: 40310-40318.
4. Bizzarri C, Holmgren A, Pekkari K, Chang G, Colotta F, Ghezzi P, Bertini R. 2005. Requirements for the different cysteines in the chemotactic and desensitizing activity of human thioredoxin. Antioxid Redox Signal 7: 1189-1194.
5. Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N, Staels B, Chinetti-Gbaguidi G. 2007. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 6: 137-143.
6. Cortes-Bratti X, Basseres E, Herrera-Rodriguez F, Botero-Kleiven S, Coppotelli G, Andersen JB, Masucci MG, Holmgren A, Chaves-Olarte E, Frisan T, Avila-Carino J. 2011. Thioredoxin 80-activated-monocytes (TAMs) inhibit the replication of intracellular pathogens. PLoS ONE 6: e16960.
7. Cuaz-Perolin C, Billiet L, Bauge E, Copin C, Scott-Algara D, Genze F, Buchele B, Syrovets T, Simmet T, Rouis M. 2008. Antiinflammatory and antiatherogenic effects of the NF-kappaB inhibitor acetyl-11-keto-beta-boswellic acid in LPS-challenged ApoE-/- mice. Arterioscler Thromb Vasc Biol 28: 272-277.
8. Cudejko C, Wouters K, Fuentes L, Hannou SA, Paquet C, Bantubungi K, Bouchaert E, Vanhoutte J, Fleury S, Remy P, Tailleux A, Chinetti-Gbaguidi G, Dombrowicz D, Staels B, Paumelle R. 2011. p16INK4a deficiency promotes IL-4-induced polarization and inhibits proinflammatory signaling in macrophages. Blood 118: 2556-2566.
9. Dessein AJ, Lenzi HL, Bina JC, Carvalho EM, Weiser WY, Andrade ZA, David JR. 1984. Modulation of eosinophil cytotoxicity by blood mononuclear cells from healthy subjects and patients with chronic schistosomiasis mansoni. Cell Immunol 85: 100-113.
10. Deussing J, Roth W, Saftig P, Peters C, Ploegh HL, Villadangos JA. 1998. Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. Proc Natl Acad Sci USA 95: 4516-4521.
11. Di Trapani G, Perkins A, Clarke F. 1998. Production and secretion of thioredoxin from transformed human trophoblast cells. Mol Hum Reprod 4: 369-375.
12. El Hadri K, Mahmood DF, Couchie D, Jguirim-Souissi I, Genze F, Diderot V, Syrovets T, Lunov O, Simmet T, Rouis M. 2012. Thioredoxin-1 promotes anti-inflammatory macrophages of the M2 phenotype and antagonizes atherosclerosis. Arterioscler Thromb Vasc Biol 32: 1445-1452.
13. Forstermann U. 2008. Oxidative stress in vascular disease: Causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med 5: 338-349.
14. Gordon S. 2003. Alternative activation of macrophages. Nat Rev Immunol 3: 23-35.
15. Gordon S. 2007. The macrophage: Past, present and future. Eur J Immunol 37: S9-S17.
16. Haendeler J, Hoffmann J, Tischler V, Berk BC, Zeiher AM, Dimmeler S. 2002. Redox regulatory and anti-apoptotic functions of thioredoxin depend on S-nitrosylation at cysteine 69. Nat Cell Biol 4: 743-749.
17. 2 stimulate degradation of thioredoxin-1: Implication for endothelial cell apoptosis. J Biol Chem 280: 42945-42951.
18. Kerblat I, Drouet C, Chesne S, Marche PN. 1999. Importance of thioredoxin in the proteolysis of an immunoglobulin G as antigen by lysosomal Cys-proteases. Immunology 97: 62-68.
19. Lemarechal H, Anract P, Beaudeux JL, Bonnefont-Rousselot D, Ekindjian OG, Borderie D. 2007. Impairment of thioredoxin reductase activity by oxidative stress in human rheumatoid synoviocytes. Free Radic Res 41: 688-698.
20. Lenzi HL, Mednis AD, Dessein AJ. 1985. Activation of human eosinophils by monokines and lymphokines: Source and biochemical characteristics of the eosinophil cytotoxicity-enhancing activity produced by blood mononuclear cells. Cell Immunol 94: 333-346.
21. Lovren F, Pan Y, Quan A, Szmitko PE, Singh KK, Shukla PC, Gupta M, Chan L, Al-Omran M, Teoh H, Verma S. 2010. Adiponectin primes human monocytes into alternative anti-inflammatory M2 macrophages. Am J Physiol Heart Circ Physiol 299: H656-H663.
22. Lumeng CN, Bodzin JL, Saltiel AR. 2007. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 117: 175-184.
23. Mantovani A, Muzio M, Garlanda C, Sozzani S, Allavena P. 2001. Macrophage control of inflammation: Negative pathways of regulation of inflammatory cytokines. Novartis Found Symp 234: 120-131; discussion 131-125.
24. Mantovani A, Sica A, Locati M. 2005. Macrophage polarization comes of age. Immunity 23: 344-346.
25. Mantovani A, Garlanda C, Locati M. 2009. Macrophage diversity and polarization in atherosclerosis: A question of balance. Arterioscler Thromb Vasc Biol 29: 1419-1423.
26. Matsunaga Y, Saibara T, Kido H, Katunuma N. 1993. Participation of cathepsin B in processing of antigen presentation to MHC class II. FEBS Lett 324: 325-330.
27. Murray PJ, Wynn TA. 2011. Obstacles and opportunities for understanding macrophage polarization. J Leukoc Biol 89: 557-563.
28. Odegaard JI, Chawla A. 2008. Mechanisms of macrophage activation in obesity-induced insulin resistance. Nat Clin Pract Endocrinol Metab 4: 619-626.
29. Ohashi K, Parker JL, Ouchi N, Higuchi A, Vita JA, Gokce N, Pedersen AA, Kalthoff C, Tullin S, Sams A, Summer R, Walsh K. 2010. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J Biol Chem 285: 6153-6160.
30. Ostos MA, Recalde D, Zakin MM, Scott-Algara D. 2002. Implication of natural killer T cells in atherosclerosis development during a LPS-induced chronic inflammation. FEBS Lett 519: 23-29.
31. Pekkari K, Holmgren A. 2004. Truncated thioredoxin: Physiological functions and mechanism. Antioxid Redox Signal 6: 53-61.
32. Pekkari K, Gurunath R, Arner ES, Holmgren A. 2000. Truncated thioredoxin is a mitogenic cytokine for resting human peripheral blood mononuclear cells and is present in human plasma. J Biol Chem 275: 37474-37480.
33. Pekkari K, Avila-Carino J, Bengtsson A, Gurunath R, Scheynius A, Holmgren A. 2001. Truncated thioredoxin (Trx80) induces production of interleukin-12 and enhances CD14 expression in human monocytes. Blood 97: 3184-3190.
34. Rodriguez GM, Diment S. 1995. Destructive proteolysis by cysteine proteases in antigen presentation of ovalbumin. Eur J Immunol 25: 1823-1827.
35. Ross R. 1999. Atherosclerosis-An inflammatory disease. N Engl J Med 340: 115-126.
36. Savill J, Dransfield I, Gregory C, Haslett C. 2002. A blast from the past: Clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2: 965-975.
37. Shioji K, Kishimoto C, Nakamura H, Masutani H, Yuan Z, Oka S, Yodoi J. 2002. Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity. Circulation 106: 1403-1409.
38. Silberstein DS, Ali MH, Baker SL, David JR. 1989. Human eosinophil cytotoxicity-enhancing factor. Purification, physical characteristics, and partial amino acid sequence of an active polypeptide. J Immunol 143: 979-983.
39. Stein M, Keshav S, Harris N, Gordon S. 1992. Interleukin 4 potently enhances murine macrophage mannose receptor activity: A marker of alternative immunologic macrophage activation. J Exp Med 176: 287-292.
40. Sullivan PM, Mezdour H, Quarfordt SH, Maeda N. 1998. Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe 2. J Clin Invest 102: 130-135.
41. Yamawaki H, Haendeler J, Berk BC. 2003. Thioredoxin: A key regulator of cardiovascular homeostasis. Circ Res 93: 1029-1033.